AstraZeneca's cancer drug Lynparza, when combined with bevacizumab, succesfully improved the amount of time patients with ovarian cancer lived without disase progression when compared with bevacizumab alone. "AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study" at 0630 GMT on Aug. 14, in the fourth paragraph, misstated the name of the drug that was combined with Lynparza. It is bevacizumab, not olaparib.

(END) Dow Jones Newswires

August 16, 2019 09:11 ET (13:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca